NCT04129255View on ClinicalTrials.gov

Octreotide LAR in the Induction of Immunologic Response in NENs Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Octreotide Acetate

administration every 28 days

Trial Locations (1)

Unknown

Istitute Nazionale Tumori - Fondazione G. Pascale, Napoli

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER

NCT04129255 - Octreotide LAR in the Induction of Immunologic Response in NENs Patients | Biotech Hunter | Biotech Hunter